The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Optimizing duration and personalization of treatment in NSCLC
Mariana Brandão, MD, PhD, Jules Bordet Institute, Brussels, Belgium, comments on the general duration of cancer treatment, which typically lasts two years but can be reduced to twelve to six months based on patient needs. She refers to cautious data from a nivolumab trial, highlighting issues related to eligibility criteria and trial design. Emphasizing the importance of personalized dosing, adjustments could be based on factors such as patient weight, and mutational analyses. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
